| 1 | metastatic | 6,016 |
| 2 | early-stage | 1,093 |
| 3 | neovascular | 515 |
| 4 | her2-positive | 424 |
| 5 | celiac | 416 |
| 6 | operable | 380 |
| 7 | node-positive | 314 |
| 8 | castration-resistant | 284 |
| 9 | er-positive | 271 |
| 10 | node-negative | 269 |
| 11 | fabry | 220 |
| 12 | late-stage | 208 |
| 13 | triple-negative | 178 |
| 14 | exudative | 160 |
| 15 | coeliac | 158 |
| 16 | er-negative | 141 |
| 17 | platinum-sensitive | 135 |
| 18 | her2-negative | 126 |
| 19 | non-metastatic | 122 |
| 20 | nonmetastatic | 119 |
| 21 | uveal | 104 |
| 22 | hormone-refractory | 96 |
| 23 | three-vessel | 94 |
| 24 | platinum-resistant | 85 |
| 25 | hormone-sensitive | 84 |
| 26 | androgen-independent | 69 |
| 27 | nonpalpable | 68 |
| 28 | hormone-receptor-positive | 67 |
| 29 | micrometastatic | 66 |
| 30 | extranodal | 64 |
| 31 | clear-cell | 63 |
| 32 | her2+ | 56 |
| 33 | pt3 | 55 |
| 34 | organ-confined | 47 |
| 35 | hormone-responsive | 40 |
| 36 | egfr-mutated | 38 |
| 37 | platinum-refractory | 33 |
| 38 | t1-2 | 33 |
| 39 | non-palpable | 32 |
| 40 | endocrine-responsive | 31 |
| 41 | her-2-positive | 31 |
| 42 | p16-positive | 31 |
| 43 | castrate-resistant | 30 |
| 44 | her2-overexpressing | 30 |
| 45 | chemotherapy-refractory | 29 |
| 46 | triple-vessel | 29 |
| 47 | egfr-mutant | 27 |
| 48 | extraprostatic | 26 |
| 49 | hr-positive | 26 |
| 50 | p16-negative | 26 |
| 51 | imatinib-resistant | 25 |
| 52 | implant-based | 23 |
| 53 | oligometastatic | 23 |
| 54 | r/m | 22 |
| 55 | tamoxifen-resistant | 22 |
| 56 | alk-positive | 21 |
| 57 | good-prognosis | 20 |
| 58 | intermediate-grade | 19 |
| 59 | locally-advanced | 19 |
| 60 | chemotherapy-resistant | 18 |
| 61 | extragonadal | 17 |
| 62 | braf-mutated | 16 |
| 63 | ct-only | 16 |
| 64 | hyperreflective | 16 |
| 65 | n0-1 | 16 |
| 66 | 2-vessel | 15 |
| 67 | her2-amplified | 15 |
| 68 | t1n0 | 15 |
| 69 | chemorefractory | 14 |
| 70 | estrogen-receptor-positive | 14 |
| 71 | hormone-resistant | 14 |
| 72 | low-stage | 14 |
| 73 | nonexudative | 14 |
| 74 | anthracycline-resistant | 13 |
| 75 | brca-associated | 13 |
| 76 | earlier-stage | 13 |
| 77 | erα-positive | 13 |
| 78 | hr-negative | 13 |
| 79 | kras-mutant | 13 |
| 80 | t3n0 | 13 |
| 81 | anderson-fabry | 12 |
| 82 | braf-mutant | 11 |
| 83 | er-poor | 11 |
| 84 | er-rich | 11 |
| 85 | ercc1-negative | 11 |
| 86 | gefitinib-resistant | 11 |
| 87 | kienböck | 11 |
| 88 | pt1n0 | 11 |
| 89 | pt3b | 11 |
| 90 | anthracycline-pretreated | 10 |
| 91 | ihc-positive | 10 |
| 92 | kras-mutated | 10 |
| 93 | msi-high | 10 |
| 94 | oestrogen-receptor-positive | 10 |
| 95 | fludarabine-refractory | 9 |
| 96 | liver-limited | 9 |
| 97 | mmr-proficient | 9 |
| 98 | taxane-pretreated | 9 |
| 99 | tay-sachs | 9 |
| 100 | egfr-expressing | 8 |
| 101 | her-2-amplified | 8 |
| 102 | hr+/her2+ | 8 |
| 103 | multiple-vessel | 8 |
| 104 | recurrent/progressive | 8 |
| 105 | trastuzumab-resistant | 8 |
| 106 | b16-bl6 | 7 |
| 107 | er+/her2- | 7 |
| 108 | erα-negative | 7 |
| 109 | estrogen-receptor-negative | 7 |
| 110 | gpc3-positive | 7 |
| 111 | her2-ve | 7 |
| 112 | her2/neu-negative | 7 |
| 113 | histologically-proven | 7 |
| 114 | imatinib-intolerant | 7 |
| 115 | legg-calvé-perthes | 7 |
| 116 | n0-n1 | 7 |
| 117 | non-organ-confined | 7 |
| 118 | pathology-confirmed | 7 |
| 119 | ph-positive | 7 |
| 120 | unfavorable-risk | 7 |
| 121 | alk-negative | 6 |
| 122 | castration-refractory | 6 |
| 123 | cytokine-refractory | 6 |
| 124 | favorable-risk | 6 |
| 125 | her-2-negative | 6 |
| 126 | hormone-receptor-negative | 6 |
| 127 | hr-positive/her2-negative | 6 |
| 128 | imatinib-resistant/-intolerant | 6 |
| 129 | irinotecan-refractory | 6 |
| 130 | kshv-infected | 6 |
| 131 | multivascular | 6 |
| 132 | pik3ca-mutant | 6 |
| 133 | radiation-treated | 6 |
| 134 | t1g3 | 6 |
| 135 | ta-t1 | 6 |
| 136 | taxane-refractory | 6 |
| 137 | tgbm | 6 |
| 138 | bap1-mutant | 5 |
| 139 | brca1-related | 5 |
| 140 | castration-sensitive | 5 |
| 141 | er-absent | 5 |
| 142 | eralpha-negative | 5 |
| 143 | erbb2-positive | 5 |
| 144 | ercc1-positive | 5 |
| 145 | fracture-induced | 5 |
| 146 | her-2-overexpressing | 5 |
| 147 | met-high | 5 |
| 148 | n0m0 | 5 |
| 149 | nonkeratinizing | 5 |
| 150 | pgr+ | 5 |
| 151 | pt3n0m0 | 5 |
| 152 | subglandular | 5 |
| 153 | t1-3n0m0 | 5 |
| 154 | t2n1m0 | 5 |
| 155 | tam-resistant | 5 |
| 156 | taxane-resistant | 5 |
| 157 | thick-filament | 5 |
| 158 | tki-resistant | 5 |
| 159 | tnf-α-activated | 5 |
| 160 | ai-resistant | 4 |
| 161 | brca1-mutated | 4 |
| 162 | brca2-associated | 4 |
| 163 | difficult-to-diagnose | 4 |
| 164 | endocrine-resistant | 4 |
| 165 | endocrine-treated | 4 |
| 166 | erb-2 | 4 |
| 167 | erα-/pr- | 4 |
| 168 | fast-proliferating | 4 |
| 169 | hormone-naïve | 4 |
| 170 | induction-refractory | 4 |
| 171 | low-to-intermediate-risk | 4 |
| 172 | lymphocyte-predominant | 4 |
| 173 | n1-2 | 4 |
| 174 | non-castrate | 4 |
| 175 | non-gcb | 4 |
| 176 | nonear | 4 |
| 177 | pt3n0 | 4 |
| 178 | raloxifene-resistant | 4 |
| 179 | tat1 | 4 |
| 180 | tp53-mutated | 4 |
| 181 | ai-naive | 3 |
| 182 | androgen-insensitive | 3 |
| 183 | anthracycline-refractory | 3 |
| 184 | bicalutamide-induced | 3 |
| 185 | brca1/2-related | 3 |
| 186 | castrate-sensitive | 3 |
| 187 | endocrine-sensitive | 3 |
| 188 | eralpha-positive | 3 |
| 189 | flat-type | 3 |
| 190 | gpc3‑expressing | 3 |
| 191 | hormone-insensitive | 3 |
| 192 | hpv/p16-positive | 3 |
| 193 | lymph-node-negative | 3 |
| 194 | m1c | 3 |
| 195 | meta-static | 3 |
| 196 | metatstatic | 3 |
| 197 | mmr-intact | 3 |
| 198 | mycn-na | 3 |
| 199 | nodal-positive | 3 |
| 200 | non-adipocytic | 3 |
| 201 | otolaryngic | 3 |
| 202 | pd-l1-negative | 3 |
| 203 | phenylephrine-preconstricted | 3 |
| 204 | positive-node | 3 |
| 205 | postdocetaxel | 3 |
| 206 | postmolar | 3 |
| 207 | pt1abn0 | 3 |
| 208 | recurrent/refractory | 3 |
| 209 | t790m-positive | 3 |
| 210 | trastuzumab-refractory | 3 |
| 211 | tx+ | 3 |
| 212 | vestibular-specific | 3 |
| 213 | 4,010 | 2 |
| 214 | 5,849 | 2 |
| 215 | 5-fu-resistant | 2 |
| 216 | 52/100 | 2 |
| 217 | 6937 | 2 |
| 218 | 9514 | 2 |
| 219 | antiestrogen-resistant | 2 |
| 220 | antihormonal-resistant | 2 |
| 221 | biochemically-recurrent | 2 |
| 222 | bone-metastatic | 2 |
| 223 | bone-residing | 2 |
| 224 | chemo-refractory | 2 |
| 225 | chiasm-sellar | 2 |
| 226 | cimp-negative | 2 |
| 227 | cish-positive | 2 |
| 228 | cured/well-controlled | 2 |
| 229 | cushings | 2 |
| 230 | del19-positive | 2 |
| 231 | docetaxel-pretreated | 2 |
| 232 | docetaxel-refractory | 2 |
| 233 | endocrine-refractory | 2 |
| 234 | erbb2-negative | 2 |
| 235 | extra-prostatic | 2 |
| 236 | fibrothoracic | 2 |
| 237 | gpnmb-overexpressing | 2 |
| 238 | hcg-triggered | 2 |
| 239 | her-positive | 2 |
| 240 | her2-/er+ | 2 |
| 241 | her2/neu-overexpressing | 2 |
| 242 | her2/neu-positive | 2 |
| 243 | histologic-proven | 2 |
| 244 | hpv-16-positive | 2 |
| 245 | ido-negative | 2 |
| 246 | in-reach | 2 |
| 247 | ipilimumab-refractory | 2 |
| 248 | irinotecan-resistant | 2 |
| 249 | lapatinib-resistant | 2 |
| 250 | laser-dissected | 2 |
| 251 | leu858arg-positive | 2 |
| 252 | levodopa-untreated | 2 |
| 253 | ln-negative | 2 |
| 254 | mcf-7-sc | 2 |
| 255 | met-amplified | 2 |
| 256 | metastatic/advanced | 2 |
| 257 | monovascular | 2 |
| 258 | mycn-amplified | 2 |
| 259 | non-papillary | 2 |
| 260 | non-tn | 2 |
| 261 | non-umn | 2 |
| 262 | nonchromophobe | 2 |
| 263 | nondisseminated | 2 |
| 264 | nonsquamous-cell | 2 |
| 265 | oestrogen-receptor-poor | 2 |
| 266 | organ-limited | 2 |
| 267 | p53-mutant | 2 |
| 268 | p95her2-negative | 2 |
| 269 | paget-schroetter | 2 |
| 270 | pathology-proven | 2 |
| 271 | perineal/perianal | 2 |
| 272 | pgr-negative | 2 |
| 273 | platinum-resistant/refractory | 2 |
| 274 | pt1/pt2 | 2 |
| 275 | pt1mic/pt1a | 2 |
| 276 | pt2-4 | 2 |
| 277 | pt3/4 | 2 |
| 278 | radioiodine-refractory | 2 |
| 279 | radiorecurrent | 2 |
| 280 | rai-refractory | 2 |
| 281 | receptor-poor | 2 |
| 282 | resecable | 2 |
| 283 | respiratory/genital | 2 |
| 284 | rrm1-negative | 2 |
| 285 | rrm1-positive | 2 |
| 286 | smoldering/indolent | 2 |
| 287 | suboptimally-debulked | 2 |
| 288 | t1,2 | 2 |
| 289 | t1-2n1m0 | 2 |
| 290 | t1c-t3b | 2 |
| 291 | t1t2n0 | 2 |
| 292 | t24t | 2 |
| 293 | t47-d | 2 |
| 294 | t790m-negative | 2 |
| 295 | t98 | 2 |
| 296 | theros | 2 |
| 297 | tim-3-negative | 2 |
| 298 | trastuzumab-pretreated | 2 |
| 299 | ''defect | 1 |
| 300 | 'blackhead | 1 |
| 301 | -unknown | 1 |
| 302 | 1-2-vessel | 1 |
| 303 | 1.2/1,000 | 1 |
| 304 | 13,323 | 1 |
| 305 | 14,284 | 1 |
| 306 | 145,600 | 1 |
| 307 | 16,178 | 1 |
| 308 | 1990-cardiovascular | 1 |
| 309 | 200-kcal | 1 |
| 310 | 20990 | 1 |
| 311 | 32/46 | 1 |
| 312 | 350/1,054 | 1 |
| 313 | 4,762 | 1 |
| 314 | 4,943 | 1 |
| 315 | 41,747 | 1 |
| 316 | 47,904 | 1 |
| 317 | 4720 | 1 |
| 318 | 5-fu-refractory | 1 |
| 319 | 7,106 | 1 |
| 320 | 7,291 | 1 |
| 321 | 8,878 | 1 |
| 322 | 9,020 | 1 |
| 323 | 9.92gy | 1 |
| 324 | 9683 | 1 |
| 325 | abacavir-associated | 1 |
| 326 | abo-hemolytic | 1 |
| 327 | adam8-negative | 1 |
| 328 | adam8-positive | 1 |
| 329 | ai-responsive | 1 |
| 330 | androgen-refractory | 1 |
| 331 | androgen-resistant | 1 |
| 332 | anthracycline-naive | 1 |
| 333 | anthropozoonotic | 1 |
| 334 | asthma/lung | 1 |
| 335 | axillary-node-negative | 1 |
| 336 | b16-bi6 | 1 |
| 337 | barrett's-related | 1 |
| 338 | bax-negative | 1 |
| 339 | bd-hemoglobin | 1 |
| 340 | bevacizumab-exposed | 1 |
| 341 | biochemical/radiographic | 1 |
| 342 | brac-positive | 1 |
| 343 | braf-mutation-positive | 1 |
| 344 | brca1-deficient | 1 |
| 345 | brca1/brca2-associated | 1 |
| 346 | breast-infiltrating | 1 |
| 347 | carcinogens-induced | 1 |
| 348 | carcinosin-tumor-derived | 1 |
| 349 | castrate-refractory | 1 |
| 350 | castration-rresistant | 1 |
| 351 | catecholamine-secreting | 1 |
| 352 | cc531 | 1 |
| 353 | cervico-mediastinal | 1 |
| 354 | chd/heart | 1 |
| 355 | chfr-low | 1 |
| 356 | clinically-detected | 1 |
| 357 | collaborations.brca1-associated | 1 |
| 358 | contactin-1 | 1 |
| 359 | coronaryheart | 1 |
| 360 | cparp-positive | 1 |
| 361 | crm-positive | 1 |
| 362 | csb-proficient | 1 |
| 363 | ct0-3 | 1 |
| 364 | ct1b-t2bn0m0 | 1 |
| 365 | ct1cn0 | 1 |
| 366 | ctis–t4a | 1 |
| 367 | cytologically-confirmed | 1 |
| 368 | cytologically-proven | 1 |
| 369 | d2f2 | 1 |
| 370 | dapsone-resistant | 1 |
| 371 | dual-vessel | 1 |
| 372 | dukes'c | 1 |
| 373 | e2-deprived | 1 |
| 374 | early-presentation | 1 |
| 375 | early/operable | 1 |
| 376 | egfr-mutation-positive | 1 |
| 377 | endocrine-dependent | 1 |
| 378 | endocrine-nonresponsive | 1 |
| 379 | endocrine-receptor-positive | 1 |
| 380 | endosonography-guided | 1 |
| 381 | er-/gata-3- | 1 |
| 382 | er-expressing | 1 |
| 383 | er-negative/prpc-positive | 1 |
| 384 | er-unknown | 1 |
| 385 | eralpha-negative/erbeta-positive | 1 |
| 386 | erbb2-expressing | 1 |
| 387 | erα-/pr+ | 1 |
| 388 | erβ+ | 1 |
| 389 | erβ-transfected | 1 |
| 390 | exudative/neovascular | 1 |
| 391 | flammatory | 1 |
| 392 | g-protein-mutant | 1 |
| 393 | galectin-3-positive | 1 |
| 394 | gpnmb-expressing | 1 |
| 395 | height-on | 1 |
| 396 | hemopathic | 1 |
| 397 | her2-overexpressed | 1 |
| 398 | her2-positive/hormone-positive | 1 |
| 399 | high-gleason-score | 1 |
| 400 | high-grade/g3 | 1 |
| 401 | high-timp-3/low-il-6 | 1 |
| 402 | higher-stage | 1 |
| 403 | hla-cw3-expressing | 1 |
| 404 | hormone-cause | 1 |
| 405 | hormonosensitive | 1 |
| 406 | hsp27-induced | 1 |
| 407 | hsp70-negative | 1 |
| 408 | hsp70-postitive | 1 |
| 409 | idh-mutant | 1 |
| 410 | initial-stage | 1 |
| 411 | intermediate-rs | 1 |
| 412 | invasive-ductal | 1 |
| 413 | invasive/metastatic | 1 |
| 414 | ipsilatelal | 1 |
| 415 | ir-based | 1 |
| 416 | irinotecan/oxaliplatin-refractory | 1 |
| 417 | juxta-facet | 1 |
| 418 | kbm5-sti | 1 |
| 419 | kras-mutation-positive | 1 |
| 420 | liver-confined | 1 |
| 421 | liver-dominant | 1 |
| 422 | liver-predominant | 1 |
| 423 | localizable | 1 |
| 424 | locoregionally-advanced | 1 |
| 425 | low-malignant-potential | 1 |
| 426 | low-risk/late-onset | 1 |
| 427 | low-timp-3/high-il-6 | 1 |
| 428 | lower-stage | 1 |
| 429 | lvi+ | 1 |
| 430 | lymph-borne | 1 |
| 431 | m1-3 | 1 |
| 432 | mcf7-bk-tr | 1 |
| 433 | mda-mb-486 | 1 |
| 434 | mda-treated | 1 |
| 435 | mda.mb.231 | 1 |
| 436 | measurable/evaluable | 1 |
| 437 | mechanical/thermal | 1 |
| 438 | mesenchymal/metaplastic | 1 |
| 439 | microdisected | 1 |
| 440 | mir-21kd | 1 |
| 441 | mono-vessel | 1 |
| 442 | mt-450 | 1 |
| 443 | multiple/advanced | 1 |
| 444 | neuroendocine | 1 |
| 445 | nm-081 | 1 |
| 446 | node-metastatic | 1 |
| 447 | node-positive/high-risk | 1 |
| 448 | nodenegative | 1 |
| 449 | non-1p/19q-deleted | 1 |
| 450 | non-oligometastatic | 1 |
| 451 | non-sight-threatening | 1 |
| 452 | non-specimen-confined | 1 |
| 453 | non-squamous-cell | 1 |
| 454 | nonamyloid | 1 |
| 455 | nonbenign | 1 |
| 456 | noncleavage | 1 |
| 457 | nonhemorrhaged | 1 |
| 458 | nonmetastasized | 1 |
| 459 | non‑metastatic | 1 |
| 460 | normal/tumour | 1 |
| 461 | nx-0mx-0 | 1 |
| 462 | oestrogen-negative | 1 |
| 463 | oestrogen-positive | 1 |
| 464 | oligodendrioglial | 1 |
| 465 | oncogene-addicted | 1 |
| 466 | organ-con-fined | 1 |
| 467 | oxaliplatin-refractory | 1 |
| 468 | p.g13d-mutated | 1 |
| 469 | p27-high | 1 |
| 470 | paralabral | 1 |
| 471 | parametrable | 1 |
| 472 | pcv-associated | 1 |
| 473 | pd-l1-positive | 1 |
| 474 | pdgfb-induced | 1 |
| 475 | plap-positive | 1 |
| 476 | pml-rarα+ | 1 |
| 477 | poorer-prognosis | 1 |
| 478 | post-dox | 1 |
| 479 | pre-cirrhotic | 1 |
| 480 | premenopausal/younger | 1 |
| 481 | primary/recurrent | 1 |
| 482 | problem-prone | 1 |
| 483 | progesterone-receptor-positive | 1 |
| 484 | ps:2 | 1 |
| 485 | pt1-2n0m0 | 1 |
| 486 | pt1/t2n0m0 | 1 |
| 487 | pt2no | 1 |
| 488 | pt3-4pn0 | 1 |
| 489 | pt3bn0m0 | 1 |
| 490 | q-linked | 1 |
| 491 | r0-resectable | 1 |
| 492 | radioiodine-resistant | 1 |
| 493 | reasons-street | 1 |
| 494 | recoveredfor | 1 |
| 495 | recurrent/advanced | 1 |
| 496 | refractory/recurrent | 1 |
| 497 | registry-contacted | 1 |
| 498 | restected | 1 |
| 499 | rrmi-positive | 1 |
| 500 | sensitizing-mutant | 1 |
| 501 | severe-stage | 1 |
| 502 | snail-mite | 1 |
| 503 | sonography-detected | 1 |
| 504 | spag9-expressing | 1 |
| 505 | sphere-cultured | 1 |
| 506 | stable/moderate | 1 |
| 507 | still-treatable | 1 |
| 508 | stress-promoted | 1 |
| 509 | survivor-established | 1 |
| 510 | t1-3n0-3m0 | 1 |
| 511 | t1-stage | 1 |
| 512 | t1b-t3 | 1 |
| 513 | t1b-t4n0 | 1 |
| 514 | t1b/t2 | 1 |
| 515 | t1t2 | 1 |
| 516 | t2-t4a-c | 1 |
| 517 | t3-4n1m0 | 1 |
| 518 | tangiers | 1 |
| 519 | taxane-treated | 1 |
| 520 | testosterone-repressed | 1 |
| 521 | three-vessels | 1 |
| 522 | thyrocardiac | 1 |
| 523 | ti-t2 | 1 |
| 524 | tis-t1 | 1 |
| 525 | tj-9-treated | 1 |
| 526 | tlr3-negative | 1 |
| 527 | trastuzumab-naive | 1 |
| 528 | tu-based | 1 |
| 529 | tumefactive | 1 |
| 530 | tumor/metastatic | 1 |
| 531 | umr-108 | 1 |
| 532 | under-estimate | 1 |
| 533 | unresponsive/recurrent | 1 |
| 534 | us-visible | 1 |
| 535 | valentini | 1 |
| 536 | veno-occlussive | 1 |
| 537 | wet-type | 1 |
| 538 | zero-vessel | 1 |
| 1 | ''defect | 1 |
| 2 | 'blackhead | 1 |
| 3 | -unknown | 1 |
| 4 | 1-2-vessel | 1 |
| 5 | 1.2/1,000 | 1 |
| 6 | 13,323 | 1 |
| 7 | 14,284 | 1 |
| 8 | 145,600 | 1 |
| 9 | 16,178 | 1 |
| 10 | 1990-cardiovascular | 1 |
| 11 | 2-vessel | 15 |
| 12 | 200-kcal | 1 |
| 13 | 20990 | 1 |
| 14 | 32/46 | 1 |
| 15 | 350/1,054 | 1 |
| 16 | 4,010 | 2 |
| 17 | 4,762 | 1 |
| 18 | 4,943 | 1 |
| 19 | 41,747 | 1 |
| 20 | 47,904 | 1 |
| 21 | 4720 | 1 |
| 22 | 5,849 | 2 |
| 23 | 5-fu-refractory | 1 |
| 24 | 5-fu-resistant | 2 |
| 25 | 52/100 | 2 |
| 26 | 6937 | 2 |
| 27 | 7,106 | 1 |
| 28 | 7,291 | 1 |
| 29 | 8,878 | 1 |
| 30 | 9,020 | 1 |
| 31 | 9.92gy | 1 |
| 32 | 9514 | 2 |
| 33 | 9683 | 1 |
| 34 | abacavir-associated | 1 |
| 35 | abo-hemolytic | 1 |
| 36 | adam8-negative | 1 |
| 37 | adam8-positive | 1 |
| 38 | ai-naive | 3 |
| 39 | ai-resistant | 4 |
| 40 | ai-responsive | 1 |
| 41 | alk-negative | 6 |
| 42 | alk-positive | 21 |
| 43 | anderson-fabry | 12 |
| 44 | androgen-independent | 69 |
| 45 | androgen-insensitive | 3 |
| 46 | androgen-refractory | 1 |
| 47 | androgen-resistant | 1 |
| 48 | anthracycline-naive | 1 |
| 49 | anthracycline-pretreated | 10 |
| 50 | anthracycline-refractory | 3 |
| 51 | anthracycline-resistant | 13 |
| 52 | anthropozoonotic | 1 |
| 53 | antiestrogen-resistant | 2 |
| 54 | antihormonal-resistant | 2 |
| 55 | asthma/lung | 1 |
| 56 | axillary-node-negative | 1 |
| 57 | b16-bi6 | 1 |
| 58 | b16-bl6 | 7 |
| 59 | bap1-mutant | 5 |
| 60 | barrett's-related | 1 |
| 61 | bax-negative | 1 |
| 62 | bd-hemoglobin | 1 |
| 63 | bevacizumab-exposed | 1 |
| 64 | bicalutamide-induced | 3 |
| 65 | biochemical/radiographic | 1 |
| 66 | biochemically-recurrent | 2 |
| 67 | bone-metastatic | 2 |
| 68 | bone-residing | 2 |
| 69 | brac-positive | 1 |
| 70 | braf-mutant | 11 |
| 71 | braf-mutated | 16 |
| 72 | braf-mutation-positive | 1 |
| 73 | brca-associated | 13 |
| 74 | brca1-deficient | 1 |
| 75 | brca1-mutated | 4 |
| 76 | brca1-related | 5 |
| 77 | brca1/2-related | 3 |
| 78 | brca1/brca2-associated | 1 |
| 79 | brca2-associated | 4 |
| 80 | breast-infiltrating | 1 |
| 81 | carcinogens-induced | 1 |
| 82 | carcinosin-tumor-derived | 1 |
| 83 | castrate-refractory | 1 |
| 84 | castrate-resistant | 30 |
| 85 | castrate-sensitive | 3 |
| 86 | castration-refractory | 6 |
| 87 | castration-resistant | 284 |
| 88 | castration-rresistant | 1 |
| 89 | castration-sensitive | 5 |
| 90 | catecholamine-secreting | 1 |
| 91 | cc531 | 1 |
| 92 | celiac | 416 |
| 93 | cervico-mediastinal | 1 |
| 94 | chd/heart | 1 |
| 95 | chemo-refractory | 2 |
| 96 | chemorefractory | 14 |
| 97 | chemotherapy-refractory | 29 |
| 98 | chemotherapy-resistant | 18 |
| 99 | chfr-low | 1 |
| 100 | chiasm-sellar | 2 |
| 101 | cimp-negative | 2 |
| 102 | cish-positive | 2 |
| 103 | clear-cell | 63 |
| 104 | clinically-detected | 1 |
| 105 | coeliac | 158 |
| 106 | collaborations.brca1-associated | 1 |
| 107 | contactin-1 | 1 |
| 108 | coronaryheart | 1 |
| 109 | cparp-positive | 1 |
| 110 | crm-positive | 1 |
| 111 | csb-proficient | 1 |
| 112 | ct-only | 16 |
| 113 | ct0-3 | 1 |
| 114 | ct1b-t2bn0m0 | 1 |
| 115 | ct1cn0 | 1 |
| 116 | ctis–t4a | 1 |
| 117 | cured/well-controlled | 2 |
| 118 | cushings | 2 |
| 119 | cytokine-refractory | 6 |
| 120 | cytologically-confirmed | 1 |
| 121 | cytologically-proven | 1 |
| 122 | d2f2 | 1 |
| 123 | dapsone-resistant | 1 |
| 124 | del19-positive | 2 |
| 125 | difficult-to-diagnose | 4 |
| 126 | docetaxel-pretreated | 2 |
| 127 | docetaxel-refractory | 2 |
| 128 | dual-vessel | 1 |
| 129 | dukes'c | 1 |
| 130 | e2-deprived | 1 |
| 131 | earlier-stage | 13 |
| 132 | early-presentation | 1 |
| 133 | early-stage | 1,093 |
| 134 | early/operable | 1 |
| 135 | egfr-expressing | 8 |
| 136 | egfr-mutant | 27 |
| 137 | egfr-mutated | 38 |
| 138 | egfr-mutation-positive | 1 |
| 139 | endocrine-dependent | 1 |
| 140 | endocrine-nonresponsive | 1 |
| 141 | endocrine-receptor-positive | 1 |
| 142 | endocrine-refractory | 2 |
| 143 | endocrine-resistant | 4 |
| 144 | endocrine-responsive | 31 |
| 145 | endocrine-sensitive | 3 |
| 146 | endocrine-treated | 4 |
| 147 | endosonography-guided | 1 |
| 148 | er+/her2- | 7 |
| 149 | er-/gata-3- | 1 |
| 150 | er-absent | 5 |
| 151 | er-expressing | 1 |
| 152 | er-negative | 141 |
| 153 | er-negative/prpc-positive | 1 |
| 154 | er-poor | 11 |
| 155 | er-positive | 271 |
| 156 | er-rich | 11 |
| 157 | er-unknown | 1 |
| 158 | eralpha-negative | 5 |
| 159 | eralpha-negative/erbeta-positive | 1 |
| 160 | eralpha-positive | 3 |
| 161 | erb-2 | 4 |
| 162 | erbb2-expressing | 1 |
| 163 | erbb2-negative | 2 |
| 164 | erbb2-positive | 5 |
| 165 | ercc1-negative | 11 |
| 166 | ercc1-positive | 5 |
| 167 | erα-/pr+ | 1 |
| 168 | erα-/pr- | 4 |
| 169 | erα-negative | 7 |
| 170 | erα-positive | 13 |
| 171 | erβ+ | 1 |
| 172 | erβ-transfected | 1 |
| 173 | estrogen-receptor-negative | 7 |
| 174 | estrogen-receptor-positive | 14 |
| 175 | extra-prostatic | 2 |
| 176 | extragonadal | 17 |
| 177 | extranodal | 64 |
| 178 | extraprostatic | 26 |
| 179 | exudative | 160 |
| 180 | exudative/neovascular | 1 |
| 181 | fabry | 220 |
| 182 | fast-proliferating | 4 |
| 183 | favorable-risk | 6 |
| 184 | fibrothoracic | 2 |
| 185 | flammatory | 1 |
| 186 | flat-type | 3 |
| 187 | fludarabine-refractory | 9 |
| 188 | fracture-induced | 5 |
| 189 | g-protein-mutant | 1 |
| 190 | galectin-3-positive | 1 |
| 191 | gefitinib-resistant | 11 |
| 192 | good-prognosis | 20 |
| 193 | gpc3-positive | 7 |
| 194 | gpc3‑expressing | 3 |
| 195 | gpnmb-expressing | 1 |
| 196 | gpnmb-overexpressing | 2 |
| 197 | hcg-triggered | 2 |
| 198 | height-on | 1 |
| 199 | hemopathic | 1 |
| 200 | her-2-amplified | 8 |
| 201 | her-2-negative | 6 |
| 202 | her-2-overexpressing | 5 |
| 203 | her-2-positive | 31 |
| 204 | her-positive | 2 |
| 205 | her2+ | 56 |
| 206 | her2-/er+ | 2 |
| 207 | her2-amplified | 15 |
| 208 | her2-negative | 126 |
| 209 | her2-overexpressed | 1 |
| 210 | her2-overexpressing | 30 |
| 211 | her2-positive | 424 |
| 212 | her2-positive/hormone-positive | 1 |
| 213 | her2-ve | 7 |
| 214 | her2/neu-negative | 7 |
| 215 | her2/neu-overexpressing | 2 |
| 216 | her2/neu-positive | 2 |
| 217 | high-gleason-score | 1 |
| 218 | high-grade/g3 | 1 |
| 219 | high-timp-3/low-il-6 | 1 |
| 220 | higher-stage | 1 |
| 221 | histologic-proven | 2 |
| 222 | histologically-proven | 7 |
| 223 | hla-cw3-expressing | 1 |
| 224 | hormone-cause | 1 |
| 225 | hormone-insensitive | 3 |
| 226 | hormone-naïve | 4 |
| 227 | hormone-receptor-negative | 6 |
| 228 | hormone-receptor-positive | 67 |
| 229 | hormone-refractory | 96 |
| 230 | hormone-resistant | 14 |
| 231 | hormone-responsive | 40 |
| 232 | hormone-sensitive | 84 |
| 233 | hormonosensitive | 1 |
| 234 | hpv-16-positive | 2 |
| 235 | hpv/p16-positive | 3 |
| 236 | hr+/her2+ | 8 |
| 237 | hr-negative | 13 |
| 238 | hr-positive | 26 |
| 239 | hr-positive/her2-negative | 6 |
| 240 | hsp27-induced | 1 |
| 241 | hsp70-negative | 1 |
| 242 | hsp70-postitive | 1 |
| 243 | hyperreflective | 16 |
| 244 | idh-mutant | 1 |
| 245 | ido-negative | 2 |
| 246 | ihc-positive | 10 |
| 247 | imatinib-intolerant | 7 |
| 248 | imatinib-resistant | 25 |
| 249 | imatinib-resistant/-intolerant | 6 |
| 250 | implant-based | 23 |
| 251 | in-reach | 2 |
| 252 | induction-refractory | 4 |
| 253 | initial-stage | 1 |
| 254 | intermediate-grade | 19 |
| 255 | intermediate-rs | 1 |
| 256 | invasive-ductal | 1 |
| 257 | invasive/metastatic | 1 |
| 258 | ipilimumab-refractory | 2 |
| 259 | ipsilatelal | 1 |
| 260 | ir-based | 1 |
| 261 | irinotecan-refractory | 6 |
| 262 | irinotecan-resistant | 2 |
| 263 | irinotecan/oxaliplatin-refractory | 1 |
| 264 | juxta-facet | 1 |
| 265 | kbm5-sti | 1 |
| 266 | kienböck | 11 |
| 267 | kras-mutant | 13 |
| 268 | kras-mutated | 10 |
| 269 | kras-mutation-positive | 1 |
| 270 | kshv-infected | 6 |
| 271 | lapatinib-resistant | 2 |
| 272 | laser-dissected | 2 |
| 273 | late-stage | 208 |
| 274 | legg-calvé-perthes | 7 |
| 275 | leu858arg-positive | 2 |
| 276 | levodopa-untreated | 2 |
| 277 | liver-confined | 1 |
| 278 | liver-dominant | 1 |
| 279 | liver-limited | 9 |
| 280 | liver-predominant | 1 |
| 281 | ln-negative | 2 |
| 282 | localizable | 1 |
| 283 | locally-advanced | 19 |
| 284 | locoregionally-advanced | 1 |
| 285 | low-malignant-potential | 1 |
| 286 | low-risk/late-onset | 1 |
| 287 | low-stage | 14 |
| 288 | low-timp-3/high-il-6 | 1 |
| 289 | low-to-intermediate-risk | 4 |
| 290 | lower-stage | 1 |
| 291 | lvi+ | 1 |
| 292 | lymph-borne | 1 |
| 293 | lymph-node-negative | 3 |
| 294 | lymphocyte-predominant | 4 |
| 295 | m1-3 | 1 |
| 296 | m1c | 3 |
| 297 | mcf-7-sc | 2 |
| 298 | mcf7-bk-tr | 1 |
| 299 | mda-mb-486 | 1 |
| 300 | mda-treated | 1 |
| 301 | mda.mb.231 | 1 |
| 302 | measurable/evaluable | 1 |
| 303 | mechanical/thermal | 1 |
| 304 | mesenchymal/metaplastic | 1 |
| 305 | met-amplified | 2 |
| 306 | met-high | 5 |
| 307 | meta-static | 3 |
| 308 | metastatic | 6,016 |
| 309 | metastatic/advanced | 2 |
| 310 | metatstatic | 3 |
| 311 | microdisected | 1 |
| 312 | micrometastatic | 66 |
| 313 | mir-21kd | 1 |
| 314 | mmr-intact | 3 |
| 315 | mmr-proficient | 9 |
| 316 | mono-vessel | 1 |
| 317 | monovascular | 2 |
| 318 | msi-high | 10 |
| 319 | mt-450 | 1 |
| 320 | multiple-vessel | 8 |
| 321 | multiple/advanced | 1 |
| 322 | multivascular | 6 |
| 323 | mycn-amplified | 2 |
| 324 | mycn-na | 3 |
| 325 | n0-1 | 16 |
| 326 | n0-n1 | 7 |
| 327 | n0m0 | 5 |
| 328 | n1-2 | 4 |
| 329 | neovascular | 515 |
| 330 | neuroendocine | 1 |
| 331 | nm-081 | 1 |
| 332 | nodal-positive | 3 |
| 333 | node-metastatic | 1 |
| 334 | node-negative | 269 |
| 335 | node-positive | 314 |
| 336 | node-positive/high-risk | 1 |
| 337 | nodenegative | 1 |
| 338 | non-1p/19q-deleted | 1 |
| 339 | non-adipocytic | 3 |
| 340 | non-castrate | 4 |
| 341 | non-gcb | 4 |
| 342 | non-metastatic | 122 |
| 343 | non-oligometastatic | 1 |
| 344 | non-organ-confined | 7 |
| 345 | non-palpable | 32 |
| 346 | non-papillary | 2 |
| 347 | non-sight-threatening | 1 |
| 348 | non-specimen-confined | 1 |
| 349 | non-squamous-cell | 1 |
| 350 | non-tn | 2 |
| 351 | non-umn | 2 |
| 352 | nonamyloid | 1 |
| 353 | nonbenign | 1 |
| 354 | nonchromophobe | 2 |
| 355 | noncleavage | 1 |
| 356 | nondisseminated | 2 |
| 357 | nonear | 4 |
| 358 | nonexudative | 14 |
| 359 | nonhemorrhaged | 1 |
| 360 | nonkeratinizing | 5 |
| 361 | nonmetastasized | 1 |
| 362 | nonmetastatic | 119 |
| 363 | nonpalpable | 68 |
| 364 | nonsquamous-cell | 2 |
| 365 | non‑metastatic | 1 |
| 366 | normal/tumour | 1 |
| 367 | nx-0mx-0 | 1 |
| 368 | oestrogen-negative | 1 |
| 369 | oestrogen-positive | 1 |
| 370 | oestrogen-receptor-poor | 2 |
| 371 | oestrogen-receptor-positive | 10 |
| 372 | oligodendrioglial | 1 |
| 373 | oligometastatic | 23 |
| 374 | oncogene-addicted | 1 |
| 375 | operable | 380 |
| 376 | organ-con-fined | 1 |
| 377 | organ-confined | 47 |
| 378 | organ-limited | 2 |
| 379 | otolaryngic | 3 |
| 380 | oxaliplatin-refractory | 1 |
| 381 | p.g13d-mutated | 1 |
| 382 | p16-negative | 26 |
| 383 | p16-positive | 31 |
| 384 | p27-high | 1 |
| 385 | p53-mutant | 2 |
| 386 | p95her2-negative | 2 |
| 387 | paget-schroetter | 2 |
| 388 | paralabral | 1 |
| 389 | parametrable | 1 |
| 390 | pathology-confirmed | 7 |
| 391 | pathology-proven | 2 |
| 392 | pcv-associated | 1 |
| 393 | pd-l1-negative | 3 |
| 394 | pd-l1-positive | 1 |
| 395 | pdgfb-induced | 1 |
| 396 | perineal/perianal | 2 |
| 397 | pgr+ | 5 |
| 398 | pgr-negative | 2 |
| 399 | ph-positive | 7 |
| 400 | phenylephrine-preconstricted | 3 |
| 401 | pik3ca-mutant | 6 |
| 402 | plap-positive | 1 |
| 403 | platinum-refractory | 33 |
| 404 | platinum-resistant | 85 |
| 405 | platinum-resistant/refractory | 2 |
| 406 | platinum-sensitive | 135 |
| 407 | pml-rarα+ | 1 |
| 408 | poorer-prognosis | 1 |
| 409 | positive-node | 3 |
| 410 | post-dox | 1 |
| 411 | postdocetaxel | 3 |
| 412 | postmolar | 3 |
| 413 | pre-cirrhotic | 1 |
| 414 | premenopausal/younger | 1 |
| 415 | primary/recurrent | 1 |
| 416 | problem-prone | 1 |
| 417 | progesterone-receptor-positive | 1 |
| 418 | ps:2 | 1 |
| 419 | pt1-2n0m0 | 1 |
| 420 | pt1/pt2 | 2 |
| 421 | pt1/t2n0m0 | 1 |
| 422 | pt1abn0 | 3 |
| 423 | pt1mic/pt1a | 2 |
| 424 | pt1n0 | 11 |
| 425 | pt2-4 | 2 |
| 426 | pt2no | 1 |
| 427 | pt3 | 55 |
| 428 | pt3-4pn0 | 1 |
| 429 | pt3/4 | 2 |
| 430 | pt3b | 11 |
| 431 | pt3bn0m0 | 1 |
| 432 | pt3n0 | 4 |
| 433 | pt3n0m0 | 5 |
| 434 | q-linked | 1 |
| 435 | r/m | 22 |
| 436 | r0-resectable | 1 |
| 437 | radiation-treated | 6 |
| 438 | radioiodine-refractory | 2 |
| 439 | radioiodine-resistant | 1 |
| 440 | radiorecurrent | 2 |
| 441 | rai-refractory | 2 |
| 442 | raloxifene-resistant | 4 |
| 443 | reasons-street | 1 |
| 444 | receptor-poor | 2 |
| 445 | recoveredfor | 1 |
| 446 | recurrent/advanced | 1 |
| 447 | recurrent/progressive | 8 |
| 448 | recurrent/refractory | 3 |
| 449 | refractory/recurrent | 1 |
| 450 | registry-contacted | 1 |
| 451 | resecable | 2 |
| 452 | respiratory/genital | 2 |
| 453 | restected | 1 |
| 454 | rrm1-negative | 2 |
| 455 | rrm1-positive | 2 |
| 456 | rrmi-positive | 1 |
| 457 | sensitizing-mutant | 1 |
| 458 | severe-stage | 1 |
| 459 | smoldering/indolent | 2 |
| 460 | snail-mite | 1 |
| 461 | sonography-detected | 1 |
| 462 | spag9-expressing | 1 |
| 463 | sphere-cultured | 1 |
| 464 | stable/moderate | 1 |
| 465 | still-treatable | 1 |
| 466 | stress-promoted | 1 |
| 467 | subglandular | 5 |
| 468 | suboptimally-debulked | 2 |
| 469 | survivor-established | 1 |
| 470 | t1,2 | 2 |
| 471 | t1-2 | 33 |
| 472 | t1-2n1m0 | 2 |
| 473 | t1-3n0-3m0 | 1 |
| 474 | t1-3n0m0 | 5 |
| 475 | t1-stage | 1 |
| 476 | t1b-t3 | 1 |
| 477 | t1b-t4n0 | 1 |
| 478 | t1b/t2 | 1 |
| 479 | t1c-t3b | 2 |
| 480 | t1g3 | 6 |
| 481 | t1n0 | 15 |
| 482 | t1t2 | 1 |
| 483 | t1t2n0 | 2 |
| 484 | t2-t4a-c | 1 |
| 485 | t24t | 2 |
| 486 | t2n1m0 | 5 |
| 487 | t3-4n1m0 | 1 |
| 488 | t3n0 | 13 |
| 489 | t47-d | 2 |
| 490 | t790m-negative | 2 |
| 491 | t790m-positive | 3 |
| 492 | t98 | 2 |
| 493 | ta-t1 | 6 |
| 494 | tam-resistant | 5 |
| 495 | tamoxifen-resistant | 22 |
| 496 | tangiers | 1 |
| 497 | tat1 | 4 |
| 498 | taxane-pretreated | 9 |
| 499 | taxane-refractory | 6 |
| 500 | taxane-resistant | 5 |
| 501 | taxane-treated | 1 |
| 502 | tay-sachs | 9 |
| 503 | testosterone-repressed | 1 |
| 504 | tgbm | 6 |
| 505 | theros | 2 |
| 506 | thick-filament | 5 |
| 507 | three-vessel | 94 |
| 508 | three-vessels | 1 |
| 509 | thyrocardiac | 1 |
| 510 | ti-t2 | 1 |
| 511 | tim-3-negative | 2 |
| 512 | tis-t1 | 1 |
| 513 | tj-9-treated | 1 |
| 514 | tki-resistant | 5 |
| 515 | tlr3-negative | 1 |
| 516 | tnf-α-activated | 5 |
| 517 | tp53-mutated | 4 |
| 518 | trastuzumab-naive | 1 |
| 519 | trastuzumab-pretreated | 2 |
| 520 | trastuzumab-refractory | 3 |
| 521 | trastuzumab-resistant | 8 |
| 522 | triple-negative | 178 |
| 523 | triple-vessel | 29 |
| 524 | tu-based | 1 |
| 525 | tumefactive | 1 |
| 526 | tumor/metastatic | 1 |
| 527 | tx+ | 3 |
| 528 | umr-108 | 1 |
| 529 | under-estimate | 1 |
| 530 | unfavorable-risk | 7 |
| 531 | unresponsive/recurrent | 1 |
| 532 | us-visible | 1 |
| 533 | uveal | 104 |
| 534 | valentini | 1 |
| 535 | veno-occlussive | 1 |
| 536 | vestibular-specific | 3 |
| 537 | wet-type | 1 |
| 538 | zero-vessel | 1 |
| 1 | her2+ | 56 |
| 2 | hr+/her2+ | 8 |
| 3 | lvi+ | 1 |
| 4 | her2-/er+ | 2 |
| 5 | pgr+ | 5 |
| 6 | erα-/pr+ | 1 |
| 7 | tx+ | 3 |
| 8 | pml-rarα+ | 1 |
| 9 | erβ+ | 1 |
| 10 | er+/her2- | 7 |
| 11 | er-/gata-3- | 1 |
| 12 | erα-/pr- | 4 |
| 13 | nx-0mx-0 | 1 |
| 14 | 1.2/1,000 | 1 |
| 15 | 52/100 | 2 |
| 16 | 145,600 | 1 |
| 17 | 4,010 | 2 |
| 18 | 9,020 | 1 |
| 19 | 4720 | 1 |
| 20 | mt-450 | 1 |
| 21 | 20990 | 1 |
| 22 | n0m0 | 5 |
| 23 | pt1-2n0m0 | 1 |
| 24 | pt1/t2n0m0 | 1 |
| 25 | t1-3n0m0 | 5 |
| 26 | pt3n0m0 | 5 |
| 27 | ct1b-t2bn0m0 | 1 |
| 28 | pt3bn0m0 | 1 |
| 29 | t1-2n1m0 | 2 |
| 30 | t2n1m0 | 5 |
| 31 | t3-4n1m0 | 1 |
| 32 | t1-3n0-3m0 | 1 |
| 33 | t1n0 | 15 |
| 34 | pt1n0 | 11 |
| 35 | t1t2n0 | 2 |
| 36 | t3n0 | 13 |
| 37 | pt3n0 | 4 |
| 38 | t1b-t4n0 | 1 |
| 39 | pt1abn0 | 3 |
| 40 | ct1cn0 | 1 |
| 41 | pt3-4pn0 | 1 |
| 42 | n0-1 | 16 |
| 43 | contactin-1 | 1 |
| 44 | mda.mb.231 | 1 |
| 45 | cc531 | 1 |
| 46 | nm-081 | 1 |
| 47 | 7,291 | 1 |
| 48 | n0-n1 | 7 |
| 49 | ta-t1 | 6 |
| 50 | tis-t1 | 1 |
| 51 | tat1 | 4 |
| 52 | t1,2 | 2 |
| 53 | n1-2 | 4 |
| 54 | t1-2 | 33 |
| 55 | erb-2 | 4 |
| 56 | 4,762 | 1 |
| 57 | ps:2 | 1 |
| 58 | d2f2 | 1 |
| 59 | ti-t2 | 1 |
| 60 | t1b/t2 | 1 |
| 61 | t1t2 | 1 |
| 62 | pt1/pt2 | 2 |
| 63 | ct0-3 | 1 |
| 64 | m1-3 | 1 |
| 65 | 13,323 | 1 |
| 66 | 4,943 | 1 |
| 67 | 9683 | 1 |
| 68 | high-grade/g3 | 1 |
| 69 | t1g3 | 6 |
| 70 | t1b-t3 | 1 |
| 71 | pt3 | 55 |
| 72 | pt2-4 | 2 |
| 73 | pt3/4 | 2 |
| 74 | 47,904 | 1 |
| 75 | 9514 | 2 |
| 76 | 350/1,054 | 1 |
| 77 | 14,284 | 1 |
| 78 | low-timp-3/high-il-6 | 1 |
| 79 | high-timp-3/low-il-6 | 1 |
| 80 | 7,106 | 1 |
| 81 | 32/46 | 1 |
| 82 | mda-mb-486 | 1 |
| 83 | b16-bi6 | 1 |
| 84 | b16-bl6 | 7 |
| 85 | 6937 | 2 |
| 86 | 41,747 | 1 |
| 87 | umr-108 | 1 |
| 88 | 16,178 | 1 |
| 89 | 8,878 | 1 |
| 90 | t98 | 2 |
| 91 | 5,849 | 2 |
| 92 | pt1mic/pt1a | 2 |
| 93 | ctis–t4a | 1 |
| 94 | mycn-na | 3 |
| 95 | t1c-t3b | 2 |
| 96 | pt3b | 11 |
| 97 | non-gcb | 4 |
| 98 | dukes'c | 1 |
| 99 | t2-t4a-c | 1 |
| 100 | m1c | 3 |
| 101 | thyrocardiac | 1 |
| 102 | celiac | 416 |
| 103 | coeliac | 158 |
| 104 | fibrothoracic | 2 |
| 105 | vestibular-specific | 3 |
| 106 | otolaryngic | 3 |
| 107 | biochemical/radiographic | 1 |
| 108 | hemopathic | 1 |
| 109 | meta-static | 3 |
| 110 | metastatic | 6,016 |
| 111 | node-metastatic | 1 |
| 112 | bone-metastatic | 2 |
| 113 | non-metastatic | 122 |
| 114 | invasive/metastatic | 1 |
| 115 | tumor/metastatic | 1 |
| 116 | nonmetastatic | 119 |
| 117 | oligometastatic | 23 |
| 118 | non-oligometastatic | 1 |
| 119 | micrometastatic | 66 |
| 120 | non‑metastatic | 1 |
| 121 | extra-prostatic | 2 |
| 122 | extraprostatic | 26 |
| 123 | metatstatic | 3 |
| 124 | pre-cirrhotic | 1 |
| 125 | anthropozoonotic | 1 |
| 126 | mesenchymal/metaplastic | 1 |
| 127 | non-adipocytic | 3 |
| 128 | abo-hemolytic | 1 |
| 129 | mcf-7-sc | 2 |
| 130 | t47-d | 2 |
| 131 | 'blackhead | 1 |
| 132 | locally-advanced | 19 |
| 133 | locoregionally-advanced | 1 |
| 134 | metastatic/advanced | 2 |
| 135 | multiple/advanced | 1 |
| 136 | recurrent/advanced | 1 |
| 137 | hsp27-induced | 1 |
| 138 | pdgfb-induced | 1 |
| 139 | bicalutamide-induced | 3 |
| 140 | fracture-induced | 5 |
| 141 | carcinogens-induced | 1 |
| 142 | endosonography-guided | 1 |
| 143 | nonhemorrhaged | 1 |
| 144 | survivor-established | 1 |
| 145 | her-2-amplified | 8 |
| 146 | her2-amplified | 15 |
| 147 | mycn-amplified | 2 |
| 148 | met-amplified | 2 |
| 149 | suboptimally-debulked | 2 |
| 150 | q-linked | 1 |
| 151 | cured/well-controlled | 2 |
| 152 | pathology-confirmed | 7 |
| 153 | cytologically-confirmed | 1 |
| 154 | organ-con-fined | 1 |
| 155 | organ-confined | 47 |
| 156 | non-organ-confined | 7 |
| 157 | non-specimen-confined | 1 |
| 158 | liver-confined | 1 |
| 159 | hcg-triggered | 2 |
| 160 | sphere-cultured | 1 |
| 161 | ir-based | 1 |
| 162 | implant-based | 23 |
| 163 | tu-based | 1 |
| 164 | bevacizumab-exposed | 1 |
| 165 | testosterone-repressed | 1 |
| 166 | her2-overexpressed | 1 |
| 167 | tj-9-treated | 1 |
| 168 | mda-treated | 1 |
| 169 | taxane-treated | 1 |
| 170 | endocrine-treated | 4 |
| 171 | radiation-treated | 6 |
| 172 | trastuzumab-pretreated | 2 |
| 173 | taxane-pretreated | 9 |
| 174 | anthracycline-pretreated | 10 |
| 175 | docetaxel-pretreated | 2 |
| 176 | levodopa-untreated | 2 |
| 177 | collaborations.brca1-associated | 1 |
| 178 | brca2-associated | 4 |
| 179 | brca1/brca2-associated | 1 |
| 180 | brca-associated | 13 |
| 181 | abacavir-associated | 1 |
| 182 | pcv-associated | 1 |
| 183 | brca1-related | 5 |
| 184 | brca1/2-related | 3 |
| 185 | barrett's-related | 1 |
| 186 | nondisseminated | 2 |
| 187 | brca1-mutated | 4 |
| 188 | tp53-mutated | 4 |
| 189 | p.g13d-mutated | 1 |
| 190 | braf-mutated | 16 |
| 191 | egfr-mutated | 38 |
| 192 | kras-mutated | 10 |
| 193 | tnf-α-activated | 5 |
| 194 | registry-contacted | 1 |
| 195 | kshv-infected | 6 |
| 196 | erβ-transfected | 1 |
| 197 | microdisected | 1 |
| 198 | laser-dissected | 2 |
| 199 | sonography-detected | 1 |
| 200 | clinically-detected | 1 |
| 201 | restected | 1 |
| 202 | oncogene-addicted | 1 |
| 203 | phenylephrine-preconstricted | 3 |
| 204 | non-1p/19q-deleted | 1 |
| 205 | organ-limited | 2 |
| 206 | liver-limited | 9 |
| 207 | stress-promoted | 1 |
| 208 | carcinosin-tumor-derived | 1 |
| 209 | e2-deprived | 1 |
| 210 | nonmetastasized | 1 |
| 211 | nonamyloid | 1 |
| 212 | mir-21kd | 1 |
| 213 | nonchromophobe | 2 |
| 214 | intermediate-grade | 19 |
| 215 | positive-node | 3 |
| 216 | t1-stage | 1 |
| 217 | severe-stage | 1 |
| 218 | late-stage | 208 |
| 219 | initial-stage | 1 |
| 220 | higher-stage | 1 |
| 221 | earlier-stage | 13 |
| 222 | lower-stage | 1 |
| 223 | low-stage | 14 |
| 224 | early-stage | 1,093 |
| 225 | noncleavage | 1 |
| 226 | resecable | 2 |
| 227 | non-palpable | 32 |
| 228 | nonpalpable | 68 |
| 229 | operable | 380 |
| 230 | early/operable | 1 |
| 231 | parametrable | 1 |
| 232 | still-treatable | 1 |
| 233 | r0-resectable | 1 |
| 234 | measurable/evaluable | 1 |
| 235 | localizable | 1 |
| 236 | us-visible | 1 |
| 237 | neuroendocine | 1 |
| 238 | problem-prone | 1 |
| 239 | lymph-borne | 1 |
| 240 | flat-type | 3 |
| 241 | wet-type | 1 |
| 242 | high-gleason-score | 1 |
| 243 | difficult-to-diagnose | 4 |
| 244 | hormone-cause | 1 |
| 245 | under-estimate | 1 |
| 246 | stable/moderate | 1 |
| 247 | non-castrate | 4 |
| 248 | snail-mite | 1 |
| 249 | her2-ve | 7 |
| 250 | trastuzumab-naive | 1 |
| 251 | anthracycline-naive | 1 |
| 252 | ai-naive | 3 |
| 253 | endocrine-responsive | 31 |
| 254 | hormone-responsive | 40 |
| 255 | ai-responsive | 1 |
| 256 | endocrine-nonresponsive | 1 |
| 257 | recurrent/progressive | 8 |
| 258 | veno-occlussive | 1 |
| 259 | exudative | 160 |
| 260 | nonexudative | 14 |
| 261 | hsp70-negative | 1 |
| 262 | ercc1-negative | 11 |
| 263 | pd-l1-negative | 3 |
| 264 | rrm1-negative | 2 |
| 265 | her-2-negative | 6 |
| 266 | erbb2-negative | 2 |
| 267 | her2-negative | 126 |
| 268 | hr-positive/her2-negative | 6 |
| 269 | p95her2-negative | 2 |
| 270 | tim-3-negative | 2 |
| 271 | tlr3-negative | 1 |
| 272 | p16-negative | 26 |
| 273 | adam8-negative | 1 |
| 274 | eralpha-negative | 5 |
| 275 | node-negative | 269 |
| 276 | lymph-node-negative | 3 |
| 277 | axillary-node-negative | 1 |
| 278 | triple-negative | 178 |
| 279 | alk-negative | 6 |
| 280 | t790m-negative | 2 |
| 281 | oestrogen-negative | 1 |
| 282 | ln-negative | 2 |
| 283 | ido-negative | 2 |
| 284 | cimp-negative | 2 |
| 285 | er-negative | 141 |
| 286 | pgr-negative | 2 |
| 287 | hr-negative | 13 |
| 288 | hormone-receptor-negative | 6 |
| 289 | estrogen-receptor-negative | 7 |
| 290 | her2/neu-negative | 7 |
| 291 | bax-negative | 1 |
| 292 | erα-negative | 7 |
| 293 | nodenegative | 1 |
| 294 | tumefactive | 1 |
| 295 | hyperreflective | 16 |
| 296 | endocrine-sensitive | 3 |
| 297 | hormone-sensitive | 84 |
| 298 | castrate-sensitive | 3 |
| 299 | platinum-sensitive | 135 |
| 300 | castration-sensitive | 5 |
| 301 | hormone-insensitive | 3 |
| 302 | androgen-insensitive | 3 |
| 303 | hormonosensitive | 1 |
| 304 | ercc1-positive | 5 |
| 305 | pd-l1-positive | 1 |
| 306 | rrm1-positive | 2 |
| 307 | her-2-positive | 31 |
| 308 | erbb2-positive | 5 |
| 309 | her2-positive | 424 |
| 310 | galectin-3-positive | 1 |
| 311 | gpc3-positive | 7 |
| 312 | hpv-16-positive | 2 |
| 313 | p16-positive | 31 |
| 314 | hpv/p16-positive | 3 |
| 315 | adam8-positive | 1 |
| 316 | del19-positive | 2 |
| 317 | eralpha-positive | 3 |
| 318 | eralpha-negative/erbeta-positive | 1 |
| 319 | brac-positive | 1 |
| 320 | ihc-positive | 10 |
| 321 | er-negative/prpc-positive | 1 |
| 322 | node-positive | 314 |
| 323 | her2-positive/hormone-positive | 1 |
| 324 | leu858arg-positive | 2 |
| 325 | ph-positive | 7 |
| 326 | cish-positive | 2 |
| 327 | rrmi-positive | 1 |
| 328 | alk-positive | 21 |
| 329 | nodal-positive | 3 |
| 330 | t790m-positive | 3 |
| 331 | crm-positive | 1 |
| 332 | oestrogen-positive | 1 |
| 333 | braf-mutation-positive | 1 |
| 334 | egfr-mutation-positive | 1 |
| 335 | kras-mutation-positive | 1 |
| 336 | plap-positive | 1 |
| 337 | cparp-positive | 1 |
| 338 | er-positive | 271 |
| 339 | her-positive | 2 |
| 340 | hr-positive | 26 |
| 341 | endocrine-receptor-positive | 1 |
| 342 | hormone-receptor-positive | 67 |
| 343 | progesterone-receptor-positive | 1 |
| 344 | estrogen-receptor-positive | 14 |
| 345 | oestrogen-receptor-positive | 10 |
| 346 | her2/neu-positive | 2 |
| 347 | erα-positive | 13 |
| 348 | hsp70-postitive | 1 |
| 349 | hormone-naïve | 4 |
| 350 | bone-residing | 2 |
| 351 | non-sight-threatening | 1 |
| 352 | erbb2-expressing | 1 |
| 353 | hla-cw3-expressing | 1 |
| 354 | spag9-expressing | 1 |
| 355 | gpnmb-expressing | 1 |
| 356 | er-expressing | 1 |
| 357 | egfr-expressing | 8 |
| 358 | her-2-overexpressing | 5 |
| 359 | her2-overexpressing | 30 |
| 360 | gpnmb-overexpressing | 2 |
| 361 | her2/neu-overexpressing | 2 |
| 362 | gpc3‑expressing | 3 |
| 363 | fast-proliferating | 4 |
| 364 | breast-infiltrating | 1 |
| 365 | catecholamine-secreting | 1 |
| 366 | nonkeratinizing | 5 |
| 367 | asthma/lung | 1 |
| 368 | in-reach | 2 |
| 369 | er-rich | 11 |
| 370 | p27-high | 1 |
| 371 | msi-high | 10 |
| 372 | met-high | 5 |
| 373 | valentini | 1 |
| 374 | kbm5-sti | 1 |
| 375 | kienböck | 11 |
| 376 | favorable-risk | 6 |
| 377 | unfavorable-risk | 7 |
| 378 | low-to-intermediate-risk | 4 |
| 379 | node-positive/high-risk | 1 |
| 380 | 200-kcal | 1 |
| 381 | extragonadal | 17 |
| 382 | extranodal | 64 |
| 383 | uveal | 104 |
| 384 | oligodendrioglial | 1 |
| 385 | low-malignant-potential | 1 |
| 386 | ipsilatelal | 1 |
| 387 | mechanical/thermal | 1 |
| 388 | perineal/perianal | 2 |
| 389 | cervico-mediastinal | 1 |
| 390 | paralabral | 1 |
| 391 | invasive-ductal | 1 |
| 392 | respiratory/genital | 2 |
| 393 | 2-vessel | 15 |
| 394 | 1-2-vessel | 1 |
| 395 | three-vessel | 94 |
| 396 | triple-vessel | 29 |
| 397 | multiple-vessel | 8 |
| 398 | dual-vessel | 1 |
| 399 | mono-vessel | 1 |
| 400 | zero-vessel | 1 |
| 401 | postdocetaxel | 3 |
| 402 | clear-cell | 63 |
| 403 | non-squamous-cell | 1 |
| 404 | nonsquamous-cell | 2 |
| 405 | r/m | 22 |
| 406 | tgbm | 6 |
| 407 | histologic-proven | 2 |
| 408 | pathology-proven | 2 |
| 409 | histologically-proven | 7 |
| 410 | cytologically-proven | 1 |
| 411 | nonbenign | 1 |
| 412 | bd-hemoglobin | 1 |
| 413 | non-umn | 2 |
| 414 | height-on | 1 |
| 415 | early-presentation | 1 |
| 416 | non-tn | 2 |
| 417 | -unknown | 1 |
| 418 | er-unknown | 1 |
| 419 | pt2no | 1 |
| 420 | nonear | 4 |
| 421 | chiasm-sellar | 2 |
| 422 | postmolar | 3 |
| 423 | multivascular | 6 |
| 424 | neovascular | 515 |
| 425 | exudative/neovascular | 1 |
| 426 | 1990-cardiovascular | 1 |
| 427 | monovascular | 2 |
| 428 | subglandular | 5 |
| 429 | premenopausal/younger | 1 |
| 430 | paget-schroetter | 2 |
| 431 | recoveredfor | 1 |
| 432 | er-poor | 11 |
| 433 | receptor-poor | 2 |
| 434 | oestrogen-receptor-poor | 2 |
| 435 | mcf7-bk-tr | 1 |
| 436 | normal/tumour | 1 |
| 437 | legg-calvé-perthes | 7 |
| 438 | cushings | 2 |
| 439 | tay-sachs | 9 |
| 440 | good-prognosis | 20 |
| 441 | poorer-prognosis | 1 |
| 442 | three-vessels | 1 |
| 443 | theros | 2 |
| 444 | intermediate-rs | 1 |
| 445 | tangiers | 1 |
| 446 | t24t | 2 |
| 447 | mmr-intact | 3 |
| 448 | ''defect | 1 |
| 449 | juxta-facet | 1 |
| 450 | reasons-street | 1 |
| 451 | low-risk/late-onset | 1 |
| 452 | liver-dominant | 1 |
| 453 | lymphocyte-predominant | 4 |
| 454 | liver-predominant | 1 |
| 455 | imatinib-resistant/-intolerant | 6 |
| 456 | imatinib-intolerant | 7 |
| 457 | trastuzumab-resistant | 8 |
| 458 | imatinib-resistant | 25 |
| 459 | lapatinib-resistant | 2 |
| 460 | gefitinib-resistant | 11 |
| 461 | taxane-resistant | 5 |
| 462 | raloxifene-resistant | 4 |
| 463 | radioiodine-resistant | 1 |
| 464 | anthracycline-resistant | 13 |
| 465 | endocrine-resistant | 4 |
| 466 | hormone-resistant | 14 |
| 467 | dapsone-resistant | 1 |
| 468 | castrate-resistant | 30 |
| 469 | ai-resistant | 4 |
| 470 | tki-resistant | 5 |
| 471 | antihormonal-resistant | 2 |
| 472 | tam-resistant | 5 |
| 473 | platinum-resistant | 85 |
| 474 | irinotecan-resistant | 2 |
| 475 | tamoxifen-resistant | 22 |
| 476 | androgen-resistant | 1 |
| 477 | antiestrogen-resistant | 2 |
| 478 | castration-resistant | 284 |
| 479 | 5-fu-resistant | 2 |
| 480 | chemotherapy-resistant | 18 |
| 481 | castration-rresistant | 1 |
| 482 | bap1-mutant | 5 |
| 483 | p53-mutant | 2 |
| 484 | pik3ca-mutant | 6 |
| 485 | braf-mutant | 11 |
| 486 | sensitizing-mutant | 1 |
| 487 | idh-mutant | 1 |
| 488 | g-protein-mutant | 1 |
| 489 | egfr-mutant | 27 |
| 490 | kras-mutant | 13 |
| 491 | endocrine-dependent | 1 |
| 492 | androgen-independent | 69 |
| 493 | brca1-deficient | 1 |
| 494 | csb-proficient | 1 |
| 495 | mmr-proficient | 9 |
| 496 | smoldering/indolent | 2 |
| 497 | thick-filament | 5 |
| 498 | biochemically-recurrent | 2 |
| 499 | unresponsive/recurrent | 1 |
| 500 | primary/recurrent | 1 |
| 501 | refractory/recurrent | 1 |
| 502 | radiorecurrent | 2 |
| 503 | er-absent | 5 |
| 504 | chd/heart | 1 |
| 505 | coronaryheart | 1 |
| 506 | chfr-low | 1 |
| 507 | post-dox | 1 |
| 508 | 9.92gy | 1 |
| 509 | ct-only | 16 |
| 510 | non-papillary | 2 |
| 511 | fabry | 220 |
| 512 | anderson-fabry | 12 |
| 513 | flammatory | 1 |
| 514 | ipilimumab-refractory | 2 |
| 515 | trastuzumab-refractory | 3 |
| 516 | taxane-refractory | 6 |
| 517 | fludarabine-refractory | 9 |
| 518 | radioiodine-refractory | 2 |
| 519 | cytokine-refractory | 6 |
| 520 | anthracycline-refractory | 3 |
| 521 | endocrine-refractory | 2 |
| 522 | hormone-refractory | 96 |
| 523 | castrate-refractory | 1 |
| 524 | rai-refractory | 2 |
| 525 | docetaxel-refractory | 2 |
| 526 | platinum-refractory | 33 |
| 527 | irinotecan-refractory | 6 |
| 528 | androgen-refractory | 1 |
| 529 | oxaliplatin-refractory | 1 |
| 530 | irinotecan/oxaliplatin-refractory | 1 |
| 531 | castration-refractory | 6 |
| 532 | induction-refractory | 4 |
| 533 | chemo-refractory | 2 |
| 534 | 5-fu-refractory | 1 |
| 535 | chemotherapy-refractory | 29 |
| 536 | platinum-resistant/refractory | 2 |
| 537 | recurrent/refractory | 3 |
| 538 | chemorefractory | 14 |